Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

High prevalence of PI resistance in patients failing second-line ART in Vietnam.

Thao VP, Quang VM, Day JN, Chinh NT, Shikuma CM, Farrar J, Van Vinh Chau N, Thwaites GE, Dunstan SJ, Le T.

J Antimicrob Chemother. 2016 Mar;71(3):762-74. doi: 10.1093/jac/dkv385. Epub 2015 Dec 11.

2.

Sustainable Synthesis of Chiral Tetrahydrofurans through the Selective Dehydration of Pentoses.

Foster RW, Tame CJ, Bučar DK, Hailes HC, Sheppard TD.

Chemistry. 2015 Nov 2;21(45):15947-50. doi: 10.1002/chem.201503510. Epub 2015 Sep 25.

3.

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.

Ross LL, Cotton MF, Cassim H, Voronin E, Givens N, Sievers J, Cheng KY; APV29005 & APV20002 Pediatric Study Groups.

Open AIDS J. 2015 May 15;9:38-44. doi: 10.2174/1874613601509010038. eCollection 2015.

4.

HIV protease inhibitors: a review of molecular selectivity and toxicity.

Lv Z, Chu Y, Wang Y.

HIV AIDS (Auckl). 2015 Apr 8;7:95-104. doi: 10.2147/HIV.S79956. eCollection 2015. Review.

5.

Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.

Huang X, Xu Y, Yang Q, Chen J, Zhang T, Li Z, Guo C, Chen H, Wu H, Li N.

Sci Rep. 2015 Feb 23;5:8528. doi: 10.1038/srep08528.

6.

Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy.

Clay PG, Crutchley RD.

Infect Dis Ther. 2014 Dec;3(2):103-22. doi: 10.1007/s40121-014-0047-5. Epub 2014 Nov 12. Review.

7.

Current perspectives in HIV post-exposure prophylaxis.

Sultan B, Benn P, Waters L.

HIV AIDS (Auckl). 2014 Oct 24;6:147-58. doi: 10.2147/HIV.S46585. eCollection 2014. Review.

8.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).

J Int AIDS Soc. 2014 Sep 25;17:19070. doi: 10.7448/IAS.17.1.19070. eCollection 2014.

9.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.

PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014. Review.

10.

Lack of protease inhibitor resistance following treatment failure--too good to be true?

Bartlett JA.

J Clin Invest. 2013 Sep;123(9):3704-5. doi: 10.1172/JCI71784. Epub 2013 Aug 27.

11.

Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.

Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW.

HIV AIDS (Auckl). 2013 Jul 15;5:153-62. doi: 10.2147/HIV.S30948. Print 2013.

12.

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.

Pediatr Infect Dis J. 2014 Jan;33(1):50-6. doi: 10.1097/INF.0b013e3182a1126a.

13.

Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.

Cotton M, Cassim H, Pavía-Ruz N, Garges HP, Perger T, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Sievers J, Cheng K.

Pediatr Infect Dis J. 2014 Jan;33(1):57-62. doi: 10.1097/INF.0b013e3182a1123a.

14.

Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.

Hernandez AV, Pasupuleti V, Deshpande A, Thota P, Collins JA, Vidal JE.

PLoS One. 2013 May 3;8(5):e63272. doi: 10.1371/journal.pone.0063272. Print 2013. Review.

15.

Challenges in initiating antiretroviral therapy in 2010.

Tremblay CL, Baril JG, Fletcher D, Kilby D, Macpherson P, Shafran SD, Tyndall MW.

Can J Infect Dis Med Microbiol. 2010 Aug;21 Suppl C:1C-15C.

16.

Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients.

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT; HOPS Investigators.

Prev Chronic Dis. 2013;10:E10. doi: 10.5888/pcd10.120083.

17.

Inhibition of HCV by the serpin antithrombin III.

Asmal M, Seaman M, Lin W, Chung RT, Letvin NL, Geiben-Lynn R.

Virol J. 2012 Oct 2;9:226. doi: 10.1186/1743-422X-9-226.

18.

Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee.

Rouleau D, Fortin C, Trottier B, Lalonde R, Lapointe N, Côté P, Routy JP, Matte MF, Tsarevsky I, Baril JG.

Can J Infect Dis Med Microbiol. 2011 Summer;22(2):52-60.

19.

Spillover adherence effects of fixed-dose combination HIV therapy.

Kauf TL, Davis KL, Earnshaw SR, Davis EA.

Patient Prefer Adherence. 2012;6:155-64. doi: 10.2147/PPA.S28482. Epub 2012 Feb 28.

20.

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML.

PLoS One. 2011;6(9):e24798. doi: 10.1371/journal.pone.0024798. Epub 2011 Sep 20.

Items per page

Supplemental Content

Write to the Help Desk